3-Methyl-8-Quinolinesulphonyl Chloride CAS 74863-82-4 Argatroban Factory

Description:

Nomen chemicum: 3-Methyl-8-Quinolinesulphonyl Chloride

CAS: 74863-82-4

Aspectus: Crystallinus Powder Alba

Puritas: >98.0% (HPLC)

Intermedia Argatroban (CAS 74863-84-6), Synthetica Thrombin Inhibitor.Antithrombotic

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum 3-Methyl-8-Quinolinesulphonyl Chloride
Synonyma 3-Methylquinoline-8-Sulfony Chloride
CAS Number 74863-82-4
CATTUS Number RF-PI269
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C10H8ClNO2S
M. Pondus 241.69
Density 1.4±0.1 g/cm3
Index refractivus 1.63
Solubilitas Solutum in Chloroforme
Shipping Condition Uit sub Ambient Temperature
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Crystallina pulveris alba
Puritas / Analysis Methodus >98.0% (HPLC)
Liquescens punctum 162.0~163.0℃
Damnum in Siccatio <0.50%
3-Methylquinoline-8-Sulfonic Acid <1.00%
Totalis immunditias <2.00%
Infrared Imaginis Conformat ut Structure
NMR Conformat ut Structure
Test Standard Enterprise Standard
Consuetudinem Medium Argatrobanum (CAS 74863-84-6).

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine & humore

commoda:

1

FAQ:

Applicatio:

Shanghai Ruifu Chemical Co., Ltd. est primarium fabrica et supplementum Chloride 3-Methyl-8-Quinolinesulphonyl (CAS: 74863-82-4) cum qualitate, late in synthesi organica adhibita, synthesis intermediorum pharmaceuticae et pharmaceuticae Ingredientis activae. (API) synthesis.Itmedium est typice in synthesi Argatroban (CAS: 74863-84-6) vel Argatroban Monohydrate (CAS 141396-28-3).

Argatroban (CAS: 74863-84-6) anticoagulans parvum moleculae inhibitoris thrombin directum est.Anno 2000, argatroban licentiatus est ab Administratione Cibus et medicamentis (FDA) prophylaxis vel curatio thrombosis patientibus heparin inductae thrombocytopenia (HIT).Anno 2002 probatum est in usu interventus coronarii percutaneos interventus aegros, qui HIT vel in periculo sunt ad eam enucleandam.Anno 2012, probatum est a MHRA in UK pro anticoagulation in patientibus heparin-ductus thrombocytopenia Type II (HIT) qui therapiam antithromboticam parenterale requirunt.

Epistulam tuam hic scribe et mitte nobis